The pig study is the last of several requirements PharmaCyte has complied with related to the requests from the US Food and Drug Administration to lift the clinical hold on PharmaCyte's planned Phase 2b clinical trial for locally advanced, inoperable pancreatic cancer.
The pilot study will involve two 90-pound Yorkshire pigs. They will receive a single intra-arterial injection of 100 CypCaps into the pancreatic arterial system through a microcatheter.
Fluoroscopy will be used to qualitatively evaluate parameters such as vascular anatomy, treatment site suitability, and acute deployment characteristics.
Over the course of a week, the animals will be clinically observed, given health and incision site checks, and body weight and condition will be scored.
At the conclusion of the clinical phase, whole blood and serum will be analyzed, and tissue will be collected including the pancreas and adjacent areas and CT imaged to evaluate potential spillover of the CypCaps containing radiopaque microspheres.
After CT imaging is performed, various tissue sections will be histologically evaluated by a board-certified veterinary pathologist.
Light microscopy will be used to examine collected tissues to evaluate for any adverse effects associated with implantation of the CypCaps.
Evaluation of pancreatic samples will include the presence of microspheres, necrosis, fibroplasia, fibrosis, inflammation, mineralization/ossification, and evidence of vascular injury.
Light microscopy of additional tissues will be reviewed to assess for adverse effects associated with treatment, including thrombosis, necrosis, inflammation, and presence of embolic material.
Both phases of the pig study are being conducted by CBSET, Inc., located in Lexington, Massachusetts.
PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer, diabetes, and malignant ascites based upon a proprietary cellulose-based live-cell encapsulation technology known as "Cell-in-a-Box."
This technology is being used as a platform upon which therapies for several types of cancer, diabetes and malignant ascites are being developed.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007